Korro Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 11/03/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.4M | $2.3M | $0 | — | $0 |
| Research and development | $65.6M | $63.6M | $57.2M | — | $42.2M |
| Operating expenses | $128.2M | $94.2M | $84.5M | — | $59.0M |
| Operating income | -$121.9M | -$91.9M | -$84.5M | — | -$59.0M |
| Interest expense | — | — | — | — | $961,000 |
| Pretax income | -$116.6M | -$83.4M | -$81.1M | — | -$58.0M |
| Income tax expense | $637,000 | $141,000 | $27,000 | — | $10,000 |
| Net income | -$117.3M | -$83.6M | -$81.2M | — | -$58.0M |
| Balance Sheet | |||||
| Cash and equivalents | $21.8M | $55.6M | $166.2M | $36.6M | $36.3M |
| Current assets | $82.4M | $131.5M | $172.7M | — | $57.1M |
| Total assets | $113.5M | $226.2M | $221.7M | — | $73.7M |
| Current liabilities | $11.9M | $15.0M | $19.5M | — | $8.7M |
| Total liabilities | $62.1M | $65.8M | $51.8M | — | $8.9M |
| Stockholders' equity | $51.4M | $160.4M | $169.9M | — | -$99.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$78.6M | -$60.1M | -$67.3M | — | -$53.6M |
| Depreciation and amortization | $4.3M | $3.6M | $3.6M | — | $2.5M |
| Stock-based compensation | $7.7M | $4.5M | $2.4M | — | $19.8M |
| Capital expenditure | $518,000 | $17.9M | $7.8M | — | $5.1M |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | — | -$58.8M |
| Impairments | $30.9M | $0 | — | — | $0 |
Shares outstanding 14.4M · Free float 43.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.